Larvol Delta - Viral-clearance-pharmacokinetics-and-tolerability-of-ensovibep-in-patients-with-mild-to-moderate-COVID19--a-phase-2a-openlabel-single-dose-escalation-study

ensovibep (MP0420) - AGC Biologics, Molecular Partners, Novartis

http://www.ncbi.nlm.nih.gov/pubmed/36214216

Oct 11, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next